Neuroene Therapeutics is a biotechnology company focused on developing innovative mitochondrial therapeutics for neurological diseases. The company's core mission is to address mitochondrial dysfunction, a key factor in various neurological disorders. Neuroene Therapeutics specializes in creating novel Vitamin K-based treatments, with a particular emphasis on conditions such as epilepsy.
Founded by C. James Chou, Ph.D., and Sherine Chan, Ph.D., from the Medical University of South Carolina, Neuroene Therapeutics emerged from collaborative research efforts. The company's approach represents a significant advancement in the field of neurology, potentially offering new solutions for patients with challenging neurological conditions. Neuroene Therapeutics continues to push the boundaries of mitochondrial medicine, aiming to improve the lives of those affected by neurological diseases.
